Breast Cancer Index’s Post

Understand how the Breast Cancer Index® test identifies patients with a low risk of late distant recurrence, helping to personalize extended endocrine therapy treatment decisions. Learn from our recent webinar to help avoid over- and under-treatment. Watch here: https://bit.ly/3zv9aPx

In this #PeerExchange, experts discuss evolving strategies in ER+/HER2– metastatic breast cancer treatment, combining endocrine and targeted therapies, and leveraging specific mutations for optimal patient outcomes. Learn more about the groundbreaking treatments here: https://bit.ly/3WdkGsj #BreastCancer

Very informative discussion and an easy win CME credits Implementing Therapeutic Intervention in High-Risk, HR-Positive/HER2-Negative Early Breast Cancer: Understanding the Prognostic Implications.

Important data from the ADAPTcycle trial on early endocrine response in HR+/HER2- presented at #SABCS2023 by PD Dr. med. Oleg Gluz ! Endocrine Response Assessment will also be implementes in the ESMO guidelines beginning of 2024 as a simple and effective tool helping to make treatment decisions for patients with early breast cancer!

Both 0, 1+, green and yellow are qualitative terms. It is impossible to tell the border between yellow and green through "eyeballing". Think about how many in-between images between 0 and 1+ (the difference is the brown staining). Pathologists are asked to find the border between 0 and 1+ every day, as only 1+ qualified a breast cancer patient for Enhertu, a $140K/year targeted therapy drug (022024)

Often described as patient ping pong, the current breast cancer diagnostic pathway can create significant delays and stress for patients that could be reduced as much as 75% with Imagio®*. Learn more at https://lnkd.in/g663k_pq #BreastCancer #optoacoustic #ImagioImaging

Experts examine the efficacy and safety profiles of elacestrant, an oral selective estrogen receptor degrader (SERD), and other options for endocrine therapy. The panelists also discuss clinical trial insights, progression-free survival rates, and tolerability, highlighting outcomes and advantages in metastatic breast cancer treatment. Watch the video series to learn more: https://bit.ly/3WdkGsj #ManagedCare #BreastCancer

Impact of BMI on implantable port access... "The purpose of this study was to investigate the association between body mass index (BMI) and the success rate of transaxillary intravenous port implantation in breast cancer patients" Shao et al (2024).

Impact of BMI on implantable port access... "The purpose of this study was to investigate the association between body mass index (BMI) and the success rate of transaxillary intravenous port implantation in breast cancer patients" Shao et al (2024).

Is exercise during cancer effective for breast cancer patients from the point of view of immunological changes? https://lnkd.in/daZ4HpD7